Intco Medical Technology's (SZSE:300677) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Intco Medical Technology's (SZSE:300677) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly amazing gains over the years. Don't believe it? Then look at the Intco Medical Technology Co., Ltd. (SZSE:300677) share price. It's 363% higher than it was five years ago. This just goes to show the value creation that some businesses can achieve. Unfortunately, though, the stock has dropped 6.9% over a week. However, this might be related to the overall market decline of 2.8% in a week.
對許多人來說,投資股市的主要目的是獲得豐厚的回報。而這些年來,我們確實看到了令人驚歎的收益。 不相信嗎?那就看看英科醫療科技有限公司(SZSE:300677)的股價。它比五年前上漲了363%。這正好說明了一些企業能夠創造的價值。 不幸的是,這隻股票在一週內下跌了6.9%。然而,這可能與整體市場在一週內下跌了2.8%有關。
While this past week has detracted from the company's five-year return, let's look at the recent trends of the underlying business and see if the gains have been in alignment.
雖然過去的一週削弱了公司的五年回報,但讓我們看看業務的最近趨勢,並查看收益是否已對齊。
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
引用本傑明·格雷厄姆的話:在短期內,市場是投票機,但在長期內,市場是稱重機。通過比較每股收益(EPS)和股票價格的時間變化,我們可以感受到投資者對公司的態度隨時間而變化。
During five years of share price growth, Intco Medical Technology achieved compound earnings per share (EPS) growth of 28% per year. This EPS growth is slower than the share price growth of 36% per year, over the same period. This suggests that market participants hold the company in higher regard, these days. That's not necessarily surprising considering the five-year track record of earnings growth.
在五年的股價增長中,英科醫療的每股收益(EPS)實現了每年28%的複合增長。這一EPS增長速度慢於同期股價36%的增長。這表明市場參與者對該公司的評價在逐漸提高。考慮到五年的盈利增長記錄,這並不令人驚訝。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
該公司的每股收益(隨時間的推移)如下圖所示(單擊可查看確切數字)。
We know that Intco Medical Technology has improved its bottom line lately, but is it going to grow revenue? If you're interested, you could check this free report showing consensus revenue forecasts.
我們知道英科醫療最近改善了其底線,但它會增長營業收入嗎?如果你感興趣,可以查看這份免費的報告,顯示一致的營業收入預測。
What About Dividends?
關於分紅派息的問題
When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for Intco Medical Technology the TSR over the last 5 years was 391%, which is better than the share price return mentioned above. This is largely a result of its dividend payments!
在考慮投資回報時,重要的是要考慮總股東回報(TSR)和股價回報之間的差異。TSR是一個回報計算,考慮到現金分紅的價值(假設收到的任何分紅都被再投資)以及任何折扣融資和剝離的計算價值。可以說,TSR提供了一個更全面的股票所產生的回報的視角。我們注意到,英科醫療在過去5年的TSR爲391%,這比上述的股價回報更好。這在很大程度上是由於其分紅支付!
A Different Perspective
另一種看法
It's good to see that Intco Medical Technology has rewarded shareholders with a total shareholder return of 28% in the last twelve months. And that does include the dividend. Having said that, the five-year TSR of 37% a year, is even better. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Intco Medical Technology you should know about.
很高興看到英科醫療在過去12個月中以28%的總股東回報獎勵了股東。並且這包括了分紅。話雖如此,五年每年37%的TSR甚至更好。我發現從長期來看股價作爲業務表現的代 proxy 是非常有趣的。但要真正獲得深入見解,我們還需要考慮其他信息。例如,考慮風險。每個公司都有風險,我們已經發現了英科醫療你應該知道的2個警告信號。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
如果您願意查看另一家公司(具有潛在的更好財務狀況),請不要錯過這個免費的公司列表,證明它們可以增長收益。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文中引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。